At a glance
ClinicalIndex Comparison RecordN/ACompleted· 42 enrolled
Drug / intervention
DS1040b +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Single Blind, Placebo-controlled, Randomized Study to Assess the Safety of DS-1040b in Subjects With Thrombectomy Treated Acute Ischemic Stroke.
In Brief
A clinical study evaluating DS1040b and Placebo for Acute Ischemic Stroke. Completed, enrolled 42 participants across 20 sites.
Detailed Summary
The aim of this study is to find out if DS-1040b is safe and tolerable in acute ischemic stroke patients with thrombectomy. Four groups will receive different doses of DS-1040b by intravenous infusion for 6 hours. Groups with the lowest dose will start. When it is determined that each dose is safe and tolerable, the next higher dose will be given to the next group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartJul 2017
Primary CompletionJan 2020
TodayJul 2026
First PostedJun 26, 2017
Enrollment StartJul 30, 2017
Primary CompletionJan 19, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.0 years ago
Interventions
DS1040bdrug
DS-1040b in solution for intravenous infusion
Placebodrug
Saline solution for intravenous infusion